Wanbury Ltd

Wanbury Ltd

₹ 146 3.14%
28 Mar - close price
About

Wanbury Ltd is primarily engaged in the manufacturing of APIs and marketing and trading of branded formulations[1][2]

Key Points

Product Portfolio
The company has two divisions API & Formulations.
APIs: The company has 13 products under its API segment which includes Metformin, Tramadol, Sertraline, Diphenhydramine Hcl, mefenamic acid, Promethazine, and others. It is also the largest manufacturer of Metformin with a capacity of 8,500 TPA.
Formulations: It sells ~70 products under various brands under this segment such as antibiotics, antiulcerants, pain management, neuropathic pain management, protein supplements, laxative, antiallergen, constipation, calcium supplement, and others. [1] [2]

  • Market Cap 479 Cr.
  • Current Price 146
  • High / Low 179 / 33.6
  • Stock P/E 20.0
  • Book Value -6.80
  • Dividend Yield 0.00 %
  • ROCE 16.9 %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.19% over past five years.
  • Promoter holding is low: 39.8%
  • Contingent liabilities of Rs.1,072 Cr.
  • Promoters have pledged 76.7% of their holding.
  • Company's cost of borrowing seems high
  • Promoter holding has decreased over last 3 years: -12.3%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
110 120 128 124 125 134 117 124 126 133 146 144 146
96 122 121 117 116 122 120 118 119 119 133 127 124
Operating Profit 14 -2 7 7 9 13 -3 6 6 14 13 17 21
OPM % 13% -1% 5% 6% 7% 10% -3% 5% 5% 11% 9% 12% 15%
1 1 0 0 0 77 2 1 0 -3 1 1 1
Interest 6 6 5 5 6 5 3 4 7 8 6 8 8
Depreciation 2 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax 6 -9 -1 -1 0 82 -7 -1 -3 1 5 7 10
Tax % 1% -0% -7% -11% 14% -1% 3% -25% -8% -11% 6% -2% -0%
6 -9 -1 -1 0 83 -7 -1 -3 1 5 7 10
EPS in Rs 2.36 -3.58 -0.26 -0.18 0.11 25.27 -2.21 -0.27 -1.00 0.31 1.43 2.25 3.14
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
386 459 661 250 420 432 370 391 367 392 511 500 569
388 491 637 228 387 414 438 375 344 374 475 476 503
Operating Profit -2 -32 25 21 33 19 -68 16 23 18 36 23 66
OPM % -1% -7% 4% 9% 8% 4% -18% 4% 6% 5% 7% 5% 12%
21 5 -78 6 0 90 76 9 84 2 77 0 -1
Interest 40 37 48 19 32 36 31 40 33 23 21 21 29
Depreciation 17 23 23 5 9 10 10 10 10 10 11 12 13
Profit before tax -39 -87 -125 4 -7 62 -32 -25 65 -12 81 -10 23
Tax % 0% -0% -2% 28% 0% 1% 1% 1% 0% -2% -0% -1%
-39 -87 -128 3 -7 62 -32 -25 64 -13 81 -10 23
EPS in Rs -22.38 -50.19 -63.95 1.60 -3.58 26.71 -13.49 -10.48 25.79 -5.04 24.94 -3.18 7.13
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 6%
3 Years: 11%
TTM: 14%
Compounded Profit Growth
10 Years: 7%
5 Years: 11%
3 Years: 13%
TTM: 557%
Stock Price CAGR
10 Years: 20%
5 Years: 46%
3 Years: 20%
1 Year: 294%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 17 17 20 20 20 23 24 24 25 25 33 33 33
Reserves 27 -65 -212 -214 -209 -176 -208 -233 -168 -181 -56 -66 -55
455 415 389 381 362 300 250 260 190 192 100 95 113
309 406 209 209 215 265 207 236 232 253 276 242 255
Total Liabilities 809 773 406 396 388 412 273 286 279 289 353 304 346
439 423 174 164 180 186 178 172 164 167 167 167 167
CWIP 17 25 13 19 14 10 10 9 14 11 2 2 10
Investments 1 1 0 0 0 0 0 0 0 0 0 0 0
352 324 219 213 193 216 84 105 101 111 183 135 169
Total Assets 809 773 406 396 388 412 273 286 279 289 353 304 346

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
9 87 68 40 43 43 32 30 44 17 41 20
-32 -21 -6 -5 -20 -13 -1 -3 64 8 1 -9
24 -64 -71 -30 -28 -27 -33 -27 -108 -17 -29 -32
Net Cash Flow 2 3 -9 5 -5 3 -2 -0 -0 7 13 -21

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 107 67 57 144 65 71 29 41 50 32 45 50
Inventory Days 113 63 42 103 69 63 27 36 25 41 60 27
Days Payable 159 114 113 301 172 260 174 209 253 221 218 179
Cash Conversion Cycle 61 15 -14 -55 -38 -125 -118 -131 -177 -148 -113 -103
Working Capital Days -165 -159 -3 -26 -45 -132 -195 -175 -212 -168 -103 -100
ROCE % -1% -11% 4% 12% 57% -1% 26% 31% 27% 46% 17%

Shareholding Pattern

Numbers in percentages

1 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
52.09% 39.90% 39.90% 39.89% 39.89% 39.85% 39.85% 39.84% 39.84% 39.84% 39.80% 39.79%
1.13% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
46.78% 60.09% 60.09% 60.11% 60.11% 60.15% 60.16% 60.16% 60.16% 60.16% 60.19% 60.20%
No. of Shareholders 11,83111,74811,58111,61911,28911,39811,55511,88811,91111,74111,63411,616

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents